Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$27.34

0.22 (0.81%)

07:31
11/22/16
11/22
07:31
11/22/16
07:31

AstraZeneca resumes enrollment for head/neck cancer trials after hold lifted

AstraZeneca announced that the U.S. FDA has lifted the partial clinical hold on the enrollment of new patients with head and neck squamous cell carcinoma for clinical trials of durvalumab as monotherapy and in combination with tremelimumab or other potential medicines. The Phase 3 KESTREL trial has already re-opened for new patient enrollment at some clinical study sites and the EAGLE trial is expected to resume recruitment shortly, without amendments to either protocol. AstraZeneca will progressively resume enrollment for all HNSCC trials across the participating sites in the U.S. and globally, subject to national health authority and ethics committee approval where required. The status of active recruitment will be reflected on clinicaltrials.gov in the coming days. The partial clinical hold on new patient enrollment was communicated on October 27, after preliminary findings from ongoing clinical trials related specifically to head and neck cancer. The FDA lifted the partial clinical hold following a review of the comprehensive analysis provided by AstraZeneca of bleeding events that were observed as part of the routine safety monitoring of the Phase 3 KESTREL and EAGLE trials.

  • 16

    Feb

AZN AstraZeneca
$27.34

0.22 (0.81%)

10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
10/20/16
JANY
10/20/16
NO CHANGE
Target $1.5
JANY
Neutral
Cerulean cash infusion gives chance to execute on programs, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Cerulean's (CERU) collaboration with Novartis (NVS), which comes with a "modest" $5M upfront payment, and its $20M ATM facility with Aspire Capital, while "not ideal," gives management a chance to execute on three of its ongoing programs, the most important of which is the dose escalation study with Olaparib with partner AstraZeneca (AZN) that should have preliminary data in 2Q17. The analyst raised his fair value estimate on Cerulean to $1.50 from $1.00 and keeps a Neutral rating on the stock.
10/26/16
PIPR
10/26/16
NO CHANGE
PIPR
Neutral
Piper still uncertain on Clovis position after AstraZeneca data
AstraZeneca's (AZN) Phase III study of Lynparza in ovarian cancer "substantially improved" progression-free survival over what was seen in study 19, suggesting a profile at least similar to TESARO's (TSRO) niraparib, Piper Jaffray analyst Steven Breazzano tells investors in a research note. The new data confirm that the various PARP inhibitors are more similar than different, which bodes well for Clovis Oncology's (CLVS) own maintenance study, the analyst contends. Breazzano, however, remains the sidelines with respect to Clovis shares given the "increasingly competitive dynamic" in ovarian cancer and uncertainty in the company's position in the important maintenance setting. The analyst keeps a Neutral rating on Clovis.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.

TODAY'S FREE FLY STORIES

APHB

AmpliPhi

$1.12

0.03 (2.75%)

17:11
01/17/18
01/17
17:11
01/17/18
17:11
Syndicate
AmpliPhi requests withdrawal of registration statement »

AmpliPhi confirms that no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$146.98

0.12 (0.08%)

17:05
01/17/18
01/17
17:05
01/17/18
17:05
Hot Stocks
Johnson & Johnson issues statement on ZYTIGA Inter Partes reviews »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

EVEP

EV Energy

$0.89

0.015 (1.71%)

17:03
01/17/18
01/17
17:03
01/17/18
17:03
Hot Stocks
EV Energy announces extension of grace period to meet NASDAQ requirement »

EV Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBM

Hudbay Minerals

$10.05

0.1 (1.01%)

17:02
01/17/18
01/17
17:02
01/17/18
17:02
Hot Stocks
Hudbay Minerals sees FY18 CapEx $245M »

Hudbay Minerals released…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFE

Safeguard Scientifics

$10.85

-0.15 (-1.36%)

17:02
01/17/18
01/17
17:02
01/17/18
17:02
Hot Stocks
Safeguard Scientifics to implement changes in business strategy and operations »

Safeguard Scientifics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$97.28

1.42 (1.48%)

, SSTI

ShotSpotter

$16.10

0.06 (0.37%)

16:55
01/17/18
01/17
16:55
01/17/18
16:55
Hot Stocks
Motorola Solutions reports 9.8% passive stake in ShotSpotter »

In a regulatory filing,…

MSI

Motorola Solutions

$97.28

1.42 (1.48%)

SSTI

ShotSpotter

$16.10

0.06 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

ERIE

Erie Indemnity

$117.23

1.44 (1.24%)

16:52
01/17/18
01/17
16:52
01/17/18
16:52
Hot Stocks
Erie Indemnity sees $20M in tax expense as a result of new tax law »

Erie Indemnity expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.10

2.91 (1.65%)

16:52
01/17/18
01/17
16:52
01/17/18
16:52
Periodicals
Apple to issue $2,500 restricted stock bonuses to workers, Bloomberg says »

Apple informed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

SLM

Sallie Mae

$11.49

0.02 (0.17%)

16:51
01/17/18
01/17
16:51
01/17/18
16:51
Earnings
Sallie Mae reports Q4 core EPS 19c, consensus 19c »

Reports Q4 GAAP net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

16:45
01/17/18
01/17
16:45
01/17/18
16:45
General news
Treasury TIC flows: foreign accounts bought $33.8 B in total U.S. assets »

Treasury TIC flows:…

VZ

Verizon

$51.72

0.06 (0.12%)

16:43
01/17/18
01/17
16:43
01/17/18
16:43
Hot Stocks
Verizon to record cumulative adjustment to retained earnings during 1Q18 »

Verizon said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

VZ

Verizon

$51.72

0.06 (0.12%)

16:42
01/17/18
01/17
16:42
01/17/18
16:42
Hot Stocks
Verizon sees $4.10 impact to FY17 EPS after tax reform »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BELFA

Bel Fuse

, BELFB

Bel Fuse

$24.70

0.25 (1.02%)

16:39
01/17/18
01/17
16:39
01/17/18
16:39
Earnings
Bel Fuse anticipates Q4 revenue $120M, 1 estimate $124M »

The company's…

BELFA

Bel Fuse

BELFB

Bel Fuse

$24.70

0.25 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:37
01/17/18
01/17
16:37
01/17/18
16:37
General news
API crude inventories for week of January 12 »

API reports that crude…

SLM

Sallie Mae

$11.49

0.02 (0.17%)

16:36
01/17/18
01/17
16:36
01/17/18
16:36
Earnings
Sallie Mae sees initial FY18 EPS 97c-$1.01, consensus $1.04 »

Sees FY18 private…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AMGP

Antero Midstream GP

$20.89

-0.11 (-0.52%)

16:36
01/17/18
01/17
16:36
01/17/18
16:36
Hot Stocks
Antero Midstream GP provides distribution guidance for 2018 through 2022 »

Antero Midstream GP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AR

Antero Resources

16:36
01/17/18
01/17
16:36
01/17/18
16:36
Hot Stocks
Antero Resources sees FY18 CapEx $1.45B »

Antero's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AR

Antero Resources

16:35
01/17/18
01/17
16:35
01/17/18
16:35
Hot Stocks
Antero Resources sees Q4 net daily gas equivalent production 2,347 MMcfe/d »

Preliminary Fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

HBHC

Hancock Holding

$54.45

0.9 (1.68%)

16:35
01/17/18
01/17
16:35
01/17/18
16:35
Earnings
Hancock Holding reports Q4 EPS with items 64c, consensus 83c »

The fourth quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AR

Antero Resources

16:34
01/17/18
01/17
16:34
01/17/18
16:34
Hot Stocks
Antero Resources sees net daily production approximately 2.7 Bcfe/d in 2018 »

2018 Guidance and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AM

Antero Midstream Partners

$30.95

-0.8 (-2.52%)

16:33
01/17/18
01/17
16:33
01/17/18
16:33
Hot Stocks
Antero Midstream Partners provides 2018 and long-term target guidance »

Antero Midstream provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

SBOW

SilverBow Resources

$31.48

0.52 (1.68%)

16:32
01/17/18
01/17
16:32
01/17/18
16:32
Hot Stocks
SilverBow Resources sees 2018 capital program of $245M-$265M »

SilverBow Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

RDN

Radian Group

$22.26

0.13 (0.59%)

16:31
01/17/18
01/17
16:31
01/17/18
16:31
Hot Stocks
Radian Group updates on capital actions »

Radian Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$54.02

0.48 (0.90%)

16:30
01/17/18
01/17
16:30
01/17/18
16:30
Initiation
Hess Corp. initiated  »

Hess Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

16:30
01/17/18
01/17
16:30
01/17/18
16:30
Options
Preliminary option volume of 23.6M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.